-+ 0.00%
-+ 0.00%
-+ 0.00%

Sarepta Therapeutics' Elevidys and Novartis' Zolgensma showed groundbreaking results, but analysts pointed out that their price list price of hundreds of millions of dollars also expanded as R&D pipelines expanded, posing affordability challenges for employers and insurance companies.

Zhitongcaijing·12/15/2025 15:49:08
Listen to the news
Sarepta Therapeutics' Elevidys and Novartis' Zolgensma showed groundbreaking results, but analysts pointed out that their price list price of hundreds of millions of dollars also expanded as R&D pipelines expanded, posing affordability challenges for employers and insurance companies.